
    
      In this clinical research trial, hLL1-DOX will be administered on days 1, 4, 8 and 11. This
      treatment cycle will be repeated every 3 weeks as long as patients continue to tolerate it,
      for a maximum of 8 treatment cycles (approximately 6 months).
    
  